Komen Scholar: Dr. Gordon Mills
Dr. Gordon Mills, Director of Precision Oncology and SMMART Trials at the Knight Cancer Institute of the Oregon Health & Science University (Portland, OR), has helped with the personalization of cancer diagnosis and treatment through his studies to understand the impact of genetic changes on the complex signaling networks in cancer. His Komen-funded research focuses on identifying and targeting pathways of drug resistance in triple negative breast cancer. Dr. Mills aims to identify and validate different combinations of therapies to enhance the effects of drugs called PARP inhibitors and increase the number of patients that can benefit from this therapy. Dr. Mills received the Brinker Award for Scientific Distinction in Basic Science in 2013 and has been a Komen Scholar since 2010.